Cancer BiologybioRxivPreprint
ZMS-6659, a selective Polθ helicase inhibitor, demonstrates anti-tumor activity as monotherapy and synergy effect with PARP inhibitors and topoisomerase inhibitors
Lei Jiang, Jiajia Li, Lu Liu…·Liting Xue
ZMS-6659, a Polθ helicase inhibitor, shows anti-tumor activity as monotherapy and synergizes with PARP inhibitors and topoisomerase inhibitors in HR-deficient and HR-proficient models.
DOI 10.1101/2025.04.19.649634